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ecombinant DNA technology has created biological organisms with advanced genetic sequences 
and has been extensively used to express multiple genes for therapeutic purposes when expressed 
in a suitable host. Microbial systems such as prokaryotic bacteria has been successfully utilized as 
a heterologous systems showing high therapeutic potency for various human diseases. Bioengineered 
bacteria have been successfully utilized for producing therapeutic proteins, treating infectious diseases, 
and disease arise due to increasing resistance to antibiotics. Prominently E. coli found to be the most widely 
used expression system for recombinant therapeutic protein production i.e. hormones, enzymes and 
antibodies. Besides E. coli, non-pathogenic lactic acid bacteria has also been considered as an excellent 
candidate for live mucosal vaccine. Likewise, S. typhimurium has been deployed as attenuated type of 
vaccination as well as in treatment strategy of various cancers due to its ability of wide progression in 
tumors. The present article is a summarized view of the main achievements and current developments in 
the field of recombinant therapeutics using bacterial strains focusing on their usability in therapeutics and 
future potential.
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Introduction  
The twentieth century has brought a lot of developments 
in the science and technology. It has been found to be 
dominated by Virchow, Lister, Koch, and Pasteur who 
brought advancements in modern medicine and 
therapeutics. Furthermore, with the advent of molecular 
techniques and Biotechnology, learning about the 
science of life using biological organisms and systems 
has improved a lot. Biotechnology includes a lot of 
disciplines i.e. seed biotechnology, recombinant gene 
development, functional genomics, applied 
immunology, as well as development of 
Biopharmaceuticals and diagnostic approaches [1]. 
An Increased understanding of the cell physiology 
and heterologous gene expression system empowered 
the use of living cells i.e. microorganisms, plants and 
animal cells as Biological factories for the development 
of recombinant molecule [2]. The idea of recombinant 
or Chimeric DNA was first proposed by Peter Lobban, a 
graduate student in the Biochemistry Department at 
Stanford University Medical School. The DNA 
sequences for constructing chimeric DNA 
(recombinant DNA) can be taken from any specie. For 
that purpose human DNA can be joined to fungal DNA 
and plant DNA can be joined to bacterial DNA for 
specific gene expressions. Such expressions required 
specialized expression vector which act as a vehicle to 
carry foreign genes needed to be expressed. 
    Among    various    specialized     vectors,    bacterial 
plasmid is considered as the most promising vector in 
recombinant DNA technology [3]. Bacterial Plasmid has 
been found to be more significant than any other vector 
in use like viral vectors. Besides bacteria, these plasmid 
vectors are also found in few fungal strains. During the 
last four decades, these plasmids have played a crucial 
role in the recombinant technology as a molecular tool 
widely used for the gene expressions in microorganisms 
and making these recombinant microbes beneficent for 
mankind [4]. 
With the advent of time, recombinant DNA 
technology has rapidly become a choice of scientists for 
treating various diseases. Using microbial genomes 
(plasmids and viral genome) as a vector, various 
successful attempts have been done which are playing 
significant roles in bringing improvements in human 
health. Bacterial attempts for therapeutic purposes has 
been initiated from last four decades [5]. A large number 
of studies have been done that prove recombinant 
Bacteria an excellent therapeutic agent. Various 
practical applications can be found in pharmaceutical 
industry including production of various human 
therapeutic proteins and various classes of antibiotics 
through molecular cloning.  In addition to that, 
recombinant bacteria has also been focused to find 
solution to various drug resistance diseases, to study the 
therapeutic efficacy of various strains in anti-cancer 
therapies as well as to find their efficacy as live mucosal 
vaccines. Many more researches are currently under 
study, expecting to bring advancement in science and 
technology, however due to the increasing need of 
innovative therapeutics, a lot of work is still need to be 
done in future. 
Methods 
For writing the article recombinant bacteria in 
therapeutics, different search engine like, PubMed, 
NCBI and Google Scholar were used. Different 
keywords i.e., enzyme production in bacteria, hormone 
production, vaccine production and antibiotic 
development in recombinant bacteria were used.  A total 
of 137 articles were collected from these search engines 
and 62 were selected and cited in writing this article. 
Discussion  
THERAPEUTIC PROTEIN PRODUCTION 
Human cells produce a large number of different 
proteins or polypeptides that get integrated into 
complex physiological network to perform specialized 
functions such as catalysts, signaling agents, structural 
components as well as regulators of inter and 
intracellular interactions [2]. The genetic mutations or 
abnormal amino acid sequences eventually cause the 
absence or dysfunctioning of respective cellular protein 
which ultimately resulted in severe diseases. Few of them 
are diabetes, dwarfism, cystic fibrosis, thalassemia, and 
impaired blood clotting [2,6]. Such diseases can be 
treated by providing missing proteins from external 
sources to reach their required concentration in the 
human body. To overcome the difficulty in obtaining 
such proteins from their natural sources, recombinant 
DNA (rDNA) technology has used bacterial strains as a 
biological framework. Using this approach several 
recombinant proteins with therapeutic applications 
have been developed prominently including insulin and 
human growth hormone [7]. For the recombinant 
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protein production, wide and growing spectrum of 
expression systems has been available [8]. E. coli is found 
to be the most widely used expression system for 
heterologous protein production due to its easiest, least 
expensive and quickest reproduction. Recent 
advancement in the understanding of Cell’s central 
dogma i.e. transcription, translation and protein folding 
along with improved genetic tools has made this 
bacterium more valuable in Microbial therapeutics. It 
has the ability to accumulate recombinant proteins up to 
80% of its dry weight and can survive under variety of 
environmental conditions [9]. 
Moreover different strains of Gram positive Lactic 
acid bacteria (LAB) have also been modified for 
therapeutic purposes [10,11]. Various strains have been 
successfully used for the production of recombinant 
proteins like Lactococcus lactis strains which  do not 
produce endotoxins and have been successfully used for 
the production of more than 100 recombinant proteins 
including expression of various potential vaccine 
components and many others [12]. Studies have also 
shown the importance of Salmonella typhimurium in 
cancer treatment as a genetically modified bacteria for 
producing anti-cancer drugs [13]. 
Hormones production 
Diabetic patients were treated with insulin purified from 
the bovine or porcine pancreas, since the early 1920s. In 
1978, the gene encoding for human insulin was first 
cloned and expressed in E. coli introducing recombinant 
human insulin as a first licensed drug. Now a days, E. 
coli and a fungi Saccharomyces cerevisiae have been used 
primarily for producing human insulin. E. coli 
expression system involves the formation of insulin 
precursors which are produced as inclusion bodies and 
become fully functional polypeptides after their 
solubilization and refolding. This functional 
polypeptide, insulin has been approved by FDA for 
therapeutic applications in humans [7]. Similarly E. coli 
expression system has also been extensively used for the 
production of recombinant hormones. Human growth 
hormone (hGH) containing 191 amino acid residues is 
a single chain polypeptide that is synthesized in the 
pituitary gland. Due to its pivotal role in a variety of 
biological functions i.e. cell proliferation and 
metabolisms, it is considered one of the most important 
hormones in the body. Studies reported on GH deficient 
patients showed that it plays a crucial role in 
maintaining mental and emotional stability by 
maintaining high energy levels [14]. For therapeutic 
purposes, exogenous recombinant hGH has been 
significantly expressed by prokaryotic expression 
system E. coli under the control of its promoter [15]. 
This exogenous hGH can be used to treat patients with 
cognitive impairment that results due to GH deficiency 
[16]. 
Enzyme production 
Enzymes are biocatalysts of cell’s metabolism that 
accelerate all biological reactions in the body. Any 
malfunction in the single critical enzyme can lead to a 
diseased condition. For instance absence of enzyme 
phenylalanine hydroxylase eventually resulted in a 
severe disorder called Phenylketonuria and causes 
mental retardation if not treated. Therefore, several 
enzymes have been produced using microbial 
expression system which cannot be synthesized in 
sufficient amount naturally. Recombinant enzymes such 
as factor VIII and Urokinase have been successfully 
produced through microbial expression system and 
provided to the patients as a drug, if their sufficient 
amount is not produced in the blood. They act as 
a thrombolytic  agents in the treatment of thrombosis 
and myocardial infarction [17].  
Streptokinase, an enzyme secreted by many 
Streptococcus species, is found to be a significant 
therapeutic agent [18]. Being widely used as a 
thrombolytic agent in treatment of acute myocardial 
infarction it has being expressed in various biological 
heterologous expression system like E. coli, Bacillus 
subtilis, Proteus mirabilis, Streptococcus lactis and 
Streptococcus sanguis. However, the recombinant 
streptokinase produced by these bacterial strains 
undergoes degradation easily [19]. L. lactis has been 
used to produce recombinant streptokinase by using its 
p170 expression system with a reduced degradation of 
that enzyme. Streptokinase gene was cloned in L. lactis 
and protein expression was controlled by changes in the 
medium composition and by pH. The expression and 
stability of recombinant streptokinase in L. lactis was 
found to be significantly increased by suppressing the 
development of ATR (acid tolerance response) in it, 
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which was basically controlled by adjusting extracellular 
pH and phosphate concentrations [18]. 
Therapeutic antibiotic production 
Antibiotic, one of the most successful forms of 
chemotherapy has contributed a lot towards the field of 
medicine. From 1950s to 1970s the period was 
considered as a golden era for the discovery of new 
classes of antibiotics. However, after 1970, with the drop 
of new drug discovery the increase in resistance of 
infectious bacteria towards the existing antibiotics was 
also observed. Many scientists observed the enzymatic 
degradation of antibiotics by microbes leading to the 
increase in multiple diseases caused by the multidrug 
resistant bacteria [20]. Moreover, the clearance of many 
pathogenic microbes by the use of broad spectrum 
antibiotics also causes the elimination of commensal 
microorganisms. These reasons lead towards various 
infections caused by opportunistic pathogens such as a 
gut infection caused by Clostridium difficile [21] and 
various other infections caused due to increased drug 
resistance in Staphylococcus aureus, Klebsiella 
pneumoniae and Mycobacterium tuberculosis etc. [22]. 
These growing antibiotic resistant problems and the 
reports of CDC on the risks of antibiotic resistance 
enforced the thought of discovering new antimicrobial 
therapies. [23]. In the past, synthetic biological 
approaches were used for producing new antibiotics 
through recombinant microbes. Clustered 
chromosomal genes coding for the enzymes of whole 
antibiotic biosynthetic pathways were cloned specially 
in bacteria and expressed at higher level. Modified and 
hybrid antibiotics were obtained by introducing desired 
genes into the non-producing strains and into the 
producers of other antibiotics [24]. Such antibiotics 
successfully gained importance in medicine market 
however hurdles in the treatment of microbial diseases 
due to growing bacterial resistance enforced the 
researchers to work on the development of new 
microbial therapeutic. Probiotics, have been engineered 
to produce targeted antimicrobials. These are specially 
designed for controlled release of these antimicrobials 
on the onset of infection. Such modifications include 
production of antimicrobial peptides, production of 
toxin receptor mimics and production of such 
antimicrobials that prevent virulent gene expression by 
disrupting Quorum sensing signals.  
RECOMBINANT BACTERIA TOWARDS 
ANTIBIOTIC RESISTANCE 
Disruption of quorum sensing signals 
Many pathogenic bacteria have the ability to 
synchronize with other bacteria by producing and 
sensing specific extracellular chemical signals. This 
chemical signaling called Quorum sensing stimulates 
the virulence regulatory genes, a coordinated behavior 
of bacteria that is dependent on their high microbial 
density. Researchers find the disruption of these QS 
signals an attractive target for prevention of diseases 
[25]. 
One of the recent works done by Duan and his co-
worker through genetic engineering approach was the 
inhibition of virulence expression of bacterial strain 
Vibrio cholera, a causative agent of intestinal disease 
Cholera. The non-pathogenic strain of E. coli was 
engineered to express cholera auto inducer CAI-1 whose 
high concentration in V. cholera infected murine model 
caused the repression of its virulence factors. This 
significantly reduced its colonization and thus was 
found to have potential to prevent disease [26]. 
Toxin receptor mimics 
Many non-pathogenic microbes have been genetically 
modified to display host receptor mimics for binding 
bacterial toxins. Recombinant probiotics were 
developed as a therapeutic strategy for prevention and 
treatment of enteric diseases through molecular 
mimicry of toxin receptors [27]. In one trial done by 
Paton and his co-workers, chimeric lipopolysaccharide 
expressed by the harmless recombinant E. coli strain was 
found capable to bind with heat-labile enterotoxins 
produced by a diarrhea causing E. coli strain. Results 
showed the considerable potential of toxin binding 
probiotics as a prophylaxis and treatment of enteric 
disease [28]. Likewise, in another trial, molecular 
mimicry of host receptors for Cholera Toxins were 
developed. The toxin receptor mimics were expressed by 
transforming the glycosyltransferase genes 
(from Campylobacter jejuni and Neisseria gonorrhoeae) 
in non-pathogenic E. coli  for the production of chimeric 
surface lipopolysaccharide expressed a mimic of the 
ganglioside GM [1]. This recombinant bacteria was 
found capable of binding cholera toxins with high 
avidity in mouse even after establishment of infection 
[29]. 
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 Antimicrobial peptides 
Many commensal bacteria have also been genetically 
modified to detect disease causing microbes and inhibit 
their growth by producing antimicrobial peptides [30]. 
In a recent work done by Borrero and his co-workers, 
recombinant lactic acid bacteria was designed to detect 
Enterococcus faecalis, a multi-resistant enterococci that 
is one of the dominant pathogens in Human GI-tract 
and respond by producing enterococcus peptides. L. 
lactis was engineered to detect enterococcal sex 
pheromone cCF10 and express genes for three 
bacteriocins, enterocin A, hiracin JM79 and enterocin P 
that showed antimicrobial activity against E. faecalis 
[31]. 
In another attempt, lactic acid bacteria was modified 
to produce antimicrobial peptides for gram negative 
pathogenic E.coli and Salmonella strains. Antimicrobial 
peptides A3APO and Alyteserin were selected on the 
basis of their high activity against E.coli and Salmonella 
strains. When these peptides were expressed in L. lactis, 
considerable reduction in pathogenic growth of these 
bacteria was observed [32]. In another work researchers 
successfully co-produced antimicrobial peptides nisin 
and colicin V through recombinant L. lactis and found 
them to be effective against both gram-positive (nisin) 
and gram negative bacteria (colicin V) [33]. Different 
trials have also been conducted on engineering those 
bacterial species that can stably colonize the 
cervicovaginal tract for treating diseases like HIV.  
Women are at higher risks for HIV infections. The 
production of an effective vaccine against HIV is 
somehow difficult to achieve due to the ability of rapid 
mutation and its evasion in the immune system. 
Researches were conducted on engineering a human 
vaginal isolate of Lactobacillus jensenii to secrete the 
HIV-1 inhibitors. In one trial Vangelista and her co-
workers engineered L. jensenii strain to secrete anti 
HIV-1 chemokine RANTES and C1C5 RANTES. Both 
RANTES variants, having correctly folded 
conformation were shown to inhibit HIV-1 infection in 
T cells and macrophages. This  recombinant bacterial 
strain was not only found to inhibit the HIV-1infection 
but also found to display strong activity against different 
HIV-1 genetic subtypes [34]. Another research work 
was conducted using the same vaginal strain L. jensenii 
to develop a live microbicide that produce antiviral 
peptide, cyanovirin-N (HIV inhibitor). It was tested on 
macaques  model. In  this  study,  macaques  were 
repeatedly colonized with recombinant L. jensenii strain 
before  each  viral  challenge.  That strain  was  shown  to 
colonize  and  secrete  CV-N  for  at  least  6  weeks  after 
administration. It was  found  to  reduce  the  rate  of 
HIV acquisition in the macaque model with a capacity 
to  provide  more  durable  protection  with  relatively 
infrequent  re-colonization.  As  healthy  women  have 
much  more  higher  levels  of Lactobacillus colonization 
in  the  cervical  mucosa  than  female  rhesus  macaques, 
this approach can lead to greater protection in humans
[35]. In another trial, a highly colonizing strain of E. coli 
was modified for the purpose of producing an antiviral 
hybrid peptide, HIV-gp41-hemolysin A hybrid peptides 
that  has the  ability  to  block  the  entry  of  HIV  into  the 
target cells by blocking its fusion [36]. 
RECOMBINANT BACTERIA AS VACCINES 
Genetically  modified  bacteria  have  been  used  not only 
for the treatment (therapeutic) but also at the same time 
for the prevention (prophylactics) of diseases.      Many  
recombinant  bacterial  strains  have been  proved  as  
effective    live    vaccines     through      heterologous 
antigens  production  and  therefore  have been found to 
evoke immune responses in various trials [23].           
Mucosal     vaccination    through       recombinant 
bacterial  strains  has  been  found  to  be  an  effective 
approach  towards  immunization  as  it  offers  many 
advantages  over  systemic  delivery  system. Mucosal 
vaccination has been found to show reduced secondary 
effects as compared to systemic vaccination [10]. 
 Salmonella, Listeria and Bordetella have been reported 
to  be  successfully  used  as  live  attenuated  vaccines  for 
delivering  heterologous  vaccines.  In  recent  trials,  a  S. 
typhimurium vaccine strain generated specific immune 
responses  in  mice  and  protect  it  against  virulent  S. 
pneumonia by expressing several pneumococcal surface 
proteins including PsaA, PspA, PspC and Ply [37]. It has 
been also found to elicit immune responses against HPV 
16 by expressing its antigens and further found to cause 
regression  of  HPV  associated  cervical  tumors  by 
expressing certain HPV associated fusion proteins [38]. 
Listeria spp. has been also found to show therapeutic and 
prophylactic  affects  against  HPV  associated  cancers 
[39]. Kong and her co-workers done study on utilizing 
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pathogenic strain for antigen delivery and have shown 
attenuated recombinant pathogenic strains to be an 
attractive candidate vaccines [40]. However few safety 
concerns are associated with them while testing with 
human as these attenuated strains have the potential to 
become virulent at any stage. Non-pathogenic, 
genetically modifiable, Lactic acid bacteria (LAB) have 
been found to be a better approach towards mucosal 
therapeutic vaccine delivery as compared to the live 
attenuated pathogens. LAB has been intensively studied 
as a candidate vector of live mucosal vaccine and large 
number of successful researches have been conducted 
on Lactobacillus and Lactococcus spp. [41].  
The first successful attempt to find killed recombinant 
Lactococci as a mucosal vaccine was done in 1990 against 
S. mutan infection. Later on, the use of live recombinant 
Lactococci against tetanus toxins was reported. Similarly 
from late 90,s large number of peer-reviewed 
publications confirmed recombinant Lactobacilli as an 
effective therapeutic vaccine [42]. Very promising 
therapeutic and prophylactic results have been shown by 
GM LAB in mouse models against HPV type 16 which 
is a major cause of cervical cancer, a second most 
common type of cancer in Women [38]. Successful 
results have been shown against HPV16 E7antigen. GM 
L. lactis strain expressing HPV 16 E7 antigen has shown 
promising results in many trials and when co-
administrated with IL-12 showed strong therapeutic 
immune responses [43]. Studies conducted on L. 
plantarum against HPV 16 E7 have shown less immune 
responses but more rapid regression of tumor than L. 
lactis strains [44]. Another strain L. casei expressing E7 
antigen has been successfully evaluated in human 
clinical trials as therapeutic vaccines [45]. L. casei has 
also shown immune responses and promising antitumor 
effects in L. casei PgSA-E6 treated mice [46]. Besides 
this, Lactobacillus sp. expressing VLPs (virus like 
particles) of HPV has opened the door for the 
development of a  new type of  vaccine [47]. Like L2 of 
HPV 16 when expressed only give immune response 
against HPV 16 but also found to show cross-
neutralizing activity against HPV-18,-45 and -58 [48]. 
In the past decade, recombinant L. casei  has been 
reported to provide  immunity  against Salmonella 
enteric serovar Enteridis  and against SARS (Severe 
Acute Respiratory Syndrome) associated coronavirus  in 
mice by expressing their respective antigens [49]. Oral 
administration of L. casei expressing  enterogenic E.coli 
(ETEC) K99, K88 fibril proteins providing  protection 
against ETEC in mice and secretion of  bioactive murine  
Interleukin-1β to give adjuvant effects are few other 
examples [50,51]. Recombinant L. lactis has been 
reported to provide immunity against Yersinia 
pseudotuberculosis infections by secreting LcrV, a 
Yersinia pseudotuberculosis low-calcium response V 
(LcrV) antigen for mucosal vaccination against Yersinia 
infections. It has been also reported to provide 
immunity against Rotavirus infection by expressing its 
Vp8 antigen and also found to have immune response 
against various parasites [43]. Besides this  recombinant 
L. lactis  has also been  found to induce protective 
immunity against different pneumococcal serotypes in 
mice by expressing its various antigens and against 
another disease, caused by Helicobacter pylori by 
expressing its antigen UreB with human IL-2 as 
adjuvant [37,52]. To generate passive immunity by 
producing antibodies various other LAB strains have 
been engineered successfully. A single-chain antibody 
fragment (ScFv) produced by recombinant L. zeae strain 
has shown to have potential to target S. mutans and 
Porphyromonas gingivali (causing periodontitis) 
antigens [43]. 
THERAPEUTICS IN CANCER TREATMENT 
Cancer, a major cause of morbidity and mortality 
worldwide, is an uncontrolled and invasive cell growth 
that can spread to the other parts of the body, a 
condition called metastasis. Conventional anti-cancer 
therapies are effective up to certain level, mostly at early 
stages but cannot cure metastatic condition [2]. Bacteria 
have been utilized from many years as anticancer agent 
and studied a lot due to their intrinsic antitumor effect 
as well as a vector system to provide therapeutic 
compounds into tumors [53,54]. Genetically modified 
non-pathogenic and attenuated bacterial strains have 
been  found to treat cancer either by providing direct 
tumoricidal effects or by delivering tumoricidal 
molecules [55]. Attenuated Salmonella typhimurium is 
the most extensively studied antitumor vector due to its  
natural ability to accumulate and replicate in a wide 
variety of solid tumors [56]. Non pathogenicity resulting 
from deletion of two of its gene msbB and purl and 
purine dependence nature make this bacterium a good 
vector for antitumor therapies. Due to its purine 
                                                               
 
 
 
                     Advancements in Life Sciences  |  www.als-journal.com  |  February 2018  | Volume 5  |  Issue 2    43  
 
als 
You’re reading 
Production of Remedial Proteins through Genetically Modified Bacteria 
dependence growth, it don’t show growth in tissues 
other than tumor cells. It can also target metastatic 
lesions. Genetically engineered S. typhimurium strains 
expressing certain murine cytokines have been found to 
retard the growth of certain melanomas. Il-2 encoding 
Salmonella organisms can suppress the growth of tumor 
more effectively than non-modified strains [57]. It has 
been studied largely as a vector for various genes coding 
IL-12, GM-CSF, IL-4, IL-18 for targeting lung cancer, 
breast cancer and various melanomas when provided 
through oral route [5]. Attenuated S. typhimurium has 
also been genetically modified to act as an imaginable 
therapeutic probe for cancer. They are bioengineered to 
generate bioluminescence signals which are used to 
monitor their migration to tumor cells to predict their 
therapeutic efficacy. Besides this non-pathogenic E.coli 
strains are also playing important role in anti-cancer 
therapies by providing a large number of antitumor 
proteins. Among 24% of all the biopharmaceutical 
proteins available in markets are the antitumor proteins 
used in cancer treatment and among the all true 
antitumor drugs 69% of the drugs are produced in E.coli 
expression system consisting of engineered and fusion 
proteins [58]. 
Many other  attenuated and engineered bacterial 
strains belonging to genus Clostridium, Bifidobacterium, 
Salmonella, Mycobacterium, Bacillus and Listeria, have 
also been found to colonize hypoxic and necrotic 
regions,  present in solid tumors and can thus 
specifically act as antitumor agents [59,60].  
Different efforts have also been done to block tumor 
angiogenesis through modified bacteria. For this 
purpose, different approaches have been utilized for the 
usage of such bacteria as anti-cancer therapeutics. This 
include bactofection, a Bacteria-mediated gene transfer 
and DNA vaccination which depend upon using 
bacterial vector [61]. Another technique is alternative 
gene therapy, which is basically a bacterial protein 
delivery mechanism for therapeutic purpose [62]. A 
bacterial S. choleraesuis strain bearing endostatin 
(angiogenesis inhibitor) and encoding eukaryotic 
expression plasmid was studied and successfully found 
to produce dual tumoricidal and antiangiogenic effects 
[5]. 
Conclusion 
Bacteria hold great importance in the field of medical 
sciences not only as a disease causing agents but have 
been found to serve mankind through several natural 
and synthetic ways. With the advent of recombinant 
DNA technology, genetic engineering has changed the 
face of pharmacology and medicine industry. The 
physiological diversity in the microbial world has 
provided a large number of biological hosts. Among the 
growing spectrum of emerging hosts, few 
microorganisms display most appealing properties as 
biological hosts in therapeutic applications. Bacterial 
cells have been successfully modified for the production 
of therapeutically important drugs, for treating various 
genetic, cancerous and multi drug resistant diseases. 
Thus genetic engineering has served as a great source of 
therapeutic agents.  
Future Prospects: The need of  improved drugs and 
innovative therapies have prompt the researchers to 
focus more on curing chronic and complex acute 
diseases by working more in this field.  They are 
constantly challenged to improve and optimize the 
existing microbial expression systems to develop more 
advanced therapeutically approaches to bring further 
advancement in medical sciences in forthcoming future 
i.e., slow releasing injectable recombinant proteins, 
chimeric protein as future drug to treat different 
problem with same drug. As protein degrades quickly 
because of their low molecular weight, the recombinant 
techniques can attach two different kind of molecules 
together to increase molecular weight, thus half-life can 
be increased. 
References 
1. Gavanji S, Begum M, Newaz AW, Dewan B, Kamal M, et al. 
Application of recombinant DNA technology—A review. 
Applied Scientific Report, (2013); 229-31. 
2. Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, 
Vázquez E, et al. Recombinant pharmaceuticals from microbial 
cells: a 2015 update. Microbial cell factories, (2016); 15(1): 1. 
3. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. 
Viral vectors: a look back and ahead on gene transfer technology. 
New Microbiol, (2013); 36(1): 1-22. 
4. Lara AR, Ramírez OT. Plasmid DNA production for therapeutic 
applications. Recombinant Gene Expression, (2012); 271-303. 
5. Gardlik R, Behuliak M, Palffy R, Celec P, Li C. Gene therapy for 
cancer: bacteria-mediated anti-angiogenesis therapy. Gene 
therapy, (2011); 18(5): 425-431. 
                        Advancements in Life Sciences  |  www.als-journal.com  |  February 2018  | Volume 5  |  Issue 2                                                          44  
 
als 
Production of Remedial Proteins through Genetically Modified Bacteria You’re reading 
6. Powell JS. Lasting power of new clotting proteins. ASH 
Education Program Book, (2014); 2014(1): 355-363. 
7. Baeshen NA, Baeshen MN, Sheikh A, Bora RS, Ahmed MMM, et 
al. Cell factories for insulin production. Microbial cell factories, 
(2014); 13(1): 1. 
8. Corchero JL, Gasser B, Resina D, Smith W, Parrilli E, et al. 
Unconventional microbial systems for the cost-efficient 
production of high-quality protein therapeutics. Biotechnology 
advances, (2013); 31(2): 140-153. 
9. Demain AL, Vaishnav P. Production of recombinant proteins by 
microbes and higher organisms. Biotechnology advances, 
(2009); 27(3): 297-306. 
10. LeBlanc JG, Aubry C, Cortes-Perez NG, de LeBlanc AdM, 
Vergnolle N, et al. Mucosal targeting of therapeutic molecules 
using genetically modified lactic acid bacteria: an update. FEMS 
microbiology letters, (2013); 344(1): 1-9. 
11. Chua KJ, Kwok WC, Aggarwal N, Sun T, Chang MW. Designer 
probiotics for the prevention and treatment of human diseases. 
Current Opinion in Chemical Biology, (2017); 40(Supplement 
C): 8-16. 
12. Glenting J, Poulsen LK, Kato K, Madsen SM, Frøkiær H, et al. 
Production of recombinant peanut allergen Ara h 2 using 
Lactococcus lactis. Microbial cell factories, (2007); 6(1): 28. 
13. Nguyen VH, Kim H-S, Ha J-M, Hong Y, Choy HE, et al. 
Genetically engineered Salmonella typhimurium as an imageable 
therapeutic probe for cancer. Cancer research, (2010); 70(1): 18-
23. 
14. Prodam F, Caputo M, Belcastro S, Garbaccio V, Zavattaro M, et 
al. Quality of life, mood disturbances and psychological 
parameters in adult patients with GH deficiency. Panminerva 
medica, (2012); 54(4): 323. 
15. Kim M-J, Park HS, Seo KH, Yang H-J, Kim S-K, et al. Complete 
solubilization and purification of recombinant human growth 
hormone produced in Escherichia coli. PLoS One, (2013); 8(2): 
e56168. 
16. Nyberg F, Hallberg M. Growth hormone and cognitive function. 
Nature Reviews Endocrinology, (2013); 9(6): 357-365. 
17. Gurung N, Ray S, Bose S, Rai V. A broader view: microbial 
enzymes and their relevance in industries, medicine, and 
beyond. BioMed research international, (2013); 2013: 329121. 
18. Jørgensen CM, Vrang A, Madsen SM. Recombinant protein 
expression in Lactococcus lactis using the P170 expression 
system. FEMS microbiology letters, (2014); 351(2): 170-178. 
19. Sriraman K, Jayaraman G. Enhancement of recombinant 
streptokinase production in Lactococcus lactis by suppression of 
acid tolerance response. Applied microbiology and 
biotechnology, (2006); 72(6): 1202-1209. 
20. Aminov RI. A brief history of the antibiotic era: lessons learned 
and challenges for the future. Frontiers in microbiology, (2010); 
1: 134. 
21. Hwang IY, Koh E, Kim HR, Yew WS, Chang MW. 
Reprogrammable microbial cell-based therapeutics against 
antibiotic-resistant bacteria. Drug Resistance Updates, (2016); 
2759-71. 
22. Banin E, Hughes D, Kuipers OP. Editorial: Bacterial pathogens, 
antibiotics and antibiotic resistance. FEMS Microbiology 
Reviews, (2017); 41(3): 450-452. 
23. Braff D, Shis D, Collins JJ. Synthetic biology platform 
technologies for antimicrobial applications. Advanced drug 
delivery reviews, (2016); 105: 35-43. 
24. Demain AL. Small bugs, big business: the economic power of the 
microbe. Biotechnology advances, (2000); 18(6): 499-514. 
25. LaSarre B, Federle MJ. Exploiting quorum sensing to confuse 
bacterial pathogens. Microbiology and Molecular Biology 
Reviews, (2013); 77(1): 73-111. 
26. Duan F, March JC. Engineered bacterial communication 
prevents Vibrio cholerae virulence in an infant mouse model. 
Proceedings of the National Academy of Sciences, (2010); 
107(25): 11260-11264. 
27. Sleator RD. Designer probiotics: Development and applications 
in gastrointestinal health. World journal of gastrointestinal 
pathophysiology, (2015); 6(3): 73. 
28. Paton AW, Jennings MP, Morona R, Wang H, Focareta A, et al. 
Recombinant probiotics for treatment and prevention of 
enterotoxigenic Escherichia coli diarrhea. Gastroenterology, 
(2005); 128(5): 1219-1228. 
29. Focareta A, Paton JC, Morona R, Cook J, Paton AW. A 
recombinant probiotic for treatment and prevention of cholera. 
Gastroenterology, (2006); 130(6): 1688-1695. 
30. Mandal SM, Silva ON, Franco OL. Recombinant probiotics with 
antimicrobial peptides: a dual strategy to improve immune 
response in immunocompromised patients. Drug discovery 
today, (2014); 19(8): 1045-1050. 
31. Borrero J, Chen Y, Dunny GM, Kaznessis YN. Modified lactic 
acid bacteria detect and inhibit multiresistant Enterococci. ACS 
synthetic biology, (2014); 4(3): 299-306. 
32. Volzing K, Borrero J, Sadowsky MJ, Kaznessis YN. 
Antimicrobial peptides targeting Gram-negative pathogens, 
produced and delivered by lactic acid bacteria. ACS synthetic 
biology, (2013); 2(11): 643-650. 
33. Buckner MM, Finlay BB. Host-microbe interaction: innate 
immunity cues virulence. Nature, (2011); 472(7342): 179-180. 
34. Vangelista L, Secchi M, Liu X, Bachi A, Jia L, et al. Engineering 
of Lactobacillus jensenii to secrete RANTES and a CCR5 
antagonist analogue as live HIV-1 blockers. Antimicrobial 
agents and chemotherapy, (2010); 54(7): 2994-3001. 
35. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, et al. 
Prevention of vaginal SHIV transmission in macaques by a live 
recombinant Lactobacillus. Mucosal immunology, (2011); 4(6): 
648-657. 
36. Rao S, Hu S, McHugh L, Lueders K, Henry K, et al. Toward a live 
microbial microbicide for HIV: commensal bacteria secreting an 
HIV fusion inhibitor peptide. Proceedings of the National 
Academy of Sciences of the United States of America, (2005); 
102(34): 11993-11998. 
37. Wang S, Curtiss III R. Development of Streptococcus 
pneumoniae vaccines using live vectors. Vaccines, (2014); 2(1): 
49-88. 
38. Gersch ED, Gissmann L, Garcea RL. New approaches to 
prophylactic human papillomavirus vaccines for cervical cancer 
prevention. Antiviral therapy, (2012); 17(3). 
39. Yoon W, Choi JH, Kim S, Park YK. Engineered Salmonella 
typhimurium expressing E7 fusion protein, derived from human 
papillomavirus, inhibits tumor growth in cervical tumor-bearing 
mice. Biotechnology letters, (2014); 36(2): 349-356. 
                                                               
 
 
 
                     Advancements in Life Sciences  |  www.als-journal.com  |  February 2018  | Volume 5  |  Issue 2    45  
 
als 
You’re reading 
Production of Remedial Proteins through Genetically Modified Bacteria 
40. Kong W, Clark-Curtiss J, Curtiss III R. Utilizing Salmonella for 
antigen delivery: the aims and benefits of bacterial delivered 
vaccination. Expert review of vaccines, (2013); 12(4): 345-347. 
41. Kumar M, Yadav AK, Verma V, Singh B, Mal G, et al. 
Bioengineered probiotics as a new hope for health and diseases: 
an overview of potential and prospects. Future microbiology, 
(2016); 11(4): 585-600. 
42. Bermúdez-Humarán LG, Kharrat P, Chatel J-M, Langella P. 
Lactococci and lactobacilli as mucosal delivery vectors for 
therapeutic proteins and DNA vaccines. Microbial cell factories, 
(2011); 10(1): 1. 
43. Michon C, Langella P, Eijsink V, Mathiesen G, Chatel J. Display 
of recombinant proteins at the surface of lactic acid bacteria: 
strategies and applications. Microbial cell factories, (2016); 
15(1): 1. 
44. Wyszyńska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka 
EK. Lactic acid bacteria—20 years exploring their potential as 
live vectors for mucosal vaccination. Applied microbiology and 
biotechnology, (2015); 99(7): 2967-2977. 
45. Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, et al. Oral 
vaccination against HPV E7 for treatment of cervical 
intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific 
mucosal immunity in the cervix of CIN3 patients. Vaccine, 
(2014); 32(47): 6233-6239. 
46. Lee TY, Kim YH, Lee KS, Kim JK, Lee IH, et al. Human 
papillomavirus type 16 E6-specific antitumor immunity is 
induced by oral administration of HPV16 E6-expressing 
Lactobacillus casei in C57BL/6 mice. Cancer immunology, 
immunotherapy, (2010); 59(11): 1727-1737. 
47. Fredriksen L, Mathiesen G, Sioud M, Eijsink VG. Cell wall 
anchoring of the 37-kilodalton oncofetal antigen by 
Lactobacillus plantarum for mucosal cancer vaccine delivery. 
Applied and environmental microbiology, (2010); 76(21): 7359-
7362. 
48. Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, et al. Oral 
administration of HPV-16 L2 displayed on Lactobacillus casei 
induces systematic and mucosal cross-neutralizing effects in 
Balb/c mice. Vaccine, (2012); 30(22): 3286-3294. 
49. Kajikawa A, Satoh E, Leer RJ, Yamamoto S, Igimi S. Intragastric 
immunization with recombinant Lactobacillus casei expressing 
flagellar antigen confers antibody-independent protective 
immunity against Salmonella enterica serovar Enteritidis. 
Vaccine, (2007); 25(18): 3599-3605. 
50. Wen LJ, Hou XL, Wang GH, Yu LY, Wei XM, et al. 
Immunization with recombinant Lactobacillus casei strains 
producing K99, K88 fimbrial protein protects mice against 
enterotoxigenic Escherichia coli. Vaccine, (2012); 30(22): 3339-
3349. 
 
 
 
 
 
 
 
 
 
51. Kajikawa A, Masuda K, Katoh M, Igimi S. Adjuvant effects for 
oral immunization provided by recombinant Lactobacillus casei 
secreting biologically active murine interleukin-1β. Clinical and 
Vaccine Immunology, (2010); 17(1): 43-48. 
52. Zhang H-x, Qiu Y-y, Zhao Y-h, Liu X-t, Liu M, et al. 
Immunogenicity of oral vaccination with Lactococcus lactis 
derived vaccine candidate antigen (UreB) of Helicobacter pylori 
fused with the human interleukin 2 as adjuvant. Molecular and 
cellular probes, (2014); 28(1): 25-30. 
53. Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in cancer 
therapy: renaissance of an old concept. International journal of 
microbiology, (2016); 2016: 8451728. 
54. Adnan M, Khan S, Al-Shammari E, Patel M, Saeed M, et al. In 
pursuit of cancer metastasis therapy by bacteria and its biofilms: 
History or future. Medical Hypotheses, (2017); 100(Supplement 
C): 78-81. 
55. Nallar SC, Xu D-Q, Kalvakolanu DV. Bacteria and genetically 
modified bacteria as cancer therapeutics: Current advances and 
challenges. Cytokine, (2016): 89; 160-172. 
56. Camacho EM, Mesa-Pereira B, Medina C, Flores A, Santero E. 
Engineering Salmonella as intracellular factory for effective 
killing of tumour cells. Scientific Reports, (2016); 6: 30591. 
57. Patyar S, Joshi R, Byrav DP, Prakash A, Medhi B, et al. Bacteria 
in cancer therapy: a novel experimental strategy. Journal of 
biomedical science, (2010); 17(1): 1. 
58. Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. 
Biologics, (2014); 813-25. 
59. Zu C, Wang J. Tumor-colonizing bacteria: a potential tumor 
targeting therapy. Critical reviews in microbiology, (2014); 
40(3): 225-235. 
60. Liu S, Xu X, Zeng X, Li L, Chen Q, et al. Tumor‑targeting 
bacterial therapy: A potential treatment for oral cancer (Review). 
Oncology letters, (2014); 8(6): 2359-2366. 
61. Larsen M, Griesenbach U, Goussard S, Gruenert D, Geddes D, et 
al. Bactofection of lung epithelial cells in vitro and in vivo using 
a genetically modified Escherichia coli. Gene therapy, (2008); 
15(6): 434-442. 
62. Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL. retraction: A 
Genetically enhanced Anaerobic Bacterium for oncopathic 
Therapy of pancreatic Cancer. Journal of the National Cancer 
Institute, (2010); 102(4): 283-283. 
 
This work is licensed under a Creative 
Commons Attribution-Non Commercial 4.0 
International License. To read the copy of this license please visit:  
https://creativecommons.org/licenses/by-nc/4.0/ 
 
 
